May 2026 Research Update

This month, the clearest new message was that some congenital hyperinsulinism (CHI) can be caused by very low-level mosaic genetic changes that are easy to miss on standard testing, but also easy to mis-call if not double-checked. In a large screening study, low-level mosaic variants were found in a small subset of people with CHI when researchers looked specifically for variants present in only a few percent of blood cells. At the same time, a notable fraction of the lowest-level sequencing signals did not hold up on confirmatory testing, showing why validation matters before a result is treated as real. [1]

The study screened blood DNA from 1252 people with CHI and compared results to 312 people with neonatal diabetes, focusing on dominant genes linked to these conditions. It reported 40 candidate low-level mosaic variants across four CHI-related genes in 39 CHI individuals, and no candidate mosaic variants in the neonatal diabetes group. When the researchers re-tested 35 of the candidates using a second method, 26 were confirmed and 9 appeared to be false positives, most often when the variant level was under 1% of DNA reads. [1]

In plain terms, these results mean that a person can have a CHI-related genetic change in only a fraction of their cells, and a blood test can sometimes detect it if the analysis is set up to look for mosaicism. They also show that extremely faint signals can be noise, so a second test may be needed to sort out true mosaic findings from false alarms. The study also noted an important open question: mosaicism might be different in other tissues than in blood, which could affect whether blood testing finds it. [1]

For patients and caregivers, this mainly adds understanding about why a genetic cause of CHI may be missed on earlier testing and why a lab might recommend confirmatory testing when a low-level variant is reported. This may matter now when families are pursuing a diagnosis and receive an unclear or low-level genetic finding, because the study shows that some low-level results do not confirm on a second test. What remains uncertain is how often mosaic variants in blood match what is happening in the pancreas or other tissues, since this work tested blood DNA and a defined set of genes. [1]

This month also included a reminder that CHI can sometimes be part of an inherited pattern where low blood sugar in infancy and diabetes later in life occur in the same family. A case report described a newborn with persistent hyperinsulinism and a family history of early-onset diabetes, where genetic testing identified a novel HNF4A variant in both the baby and the mother. Because it is a single family and the variant was not functionally tested in the lab, it is best read as an example of what can happen rather than a result that applies to most people with CHI. [2]

In this report, sequencing found a previously unreported HNF4A change (c.598G>C; p.Ala222Pro), and Sanger testing confirmed it in the child and the mother, supporting an inherited explanation for the different blood sugar problems in the family. The authors described the newborn as having persistent hyperinsulinism and discussed how the genetic result could inform thinking about diabetes treatment options for the mother. The report also clearly noted that the variant classification relied on computer-based predictions rather than direct functional validation. [2]

For families, this case may matter when CHI and early-onset diabetes appear together across relatives, because it shows one way a shared genetic explanation can connect both. Right now, the evidence is limited to a single family, so it mainly serves as a signal that genetic testing can sometimes clarify why different relatives have different blood sugar issues at different ages. What remains uncertain is whether this exact new HNF4A variant behaves the same way in other people, since the report did not include laboratory functional testing. [2]